Lipid-Based Nanocarriers in the Treatment of Glioblastoma Multiforme (GBM): Challenges and Opportunities

Gupta, Tanisha; Sahoo, Rakesh Kumar; Singh, Himani; Katke, Sumeet; Chaurasiya, Akash; Gupta, Umesh

doi:10.1208/s12249-023-02555-2

Cited by 5 publications

(1 citation statement)

References 146 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During the past decades, liposomes have been widely tested for drug delivery to the brain [ 16 , 17 , 18 , 19 , 20 ]. A number of pharmaceutical studies have demonstrated the many advantages of liposomes, including good biocompatibility, biodegradability, flexibility in size and surface charge, and versatility for various applications, making them an advanced nanocarrier system for targeted drug delivery [ 21 , 22 , 23 ].…”

Section: Introductionmentioning

confidence: 99%

In Vitro and In Vivo Evaluation of Lactoferrin-Modified Liposomal Etomidate with Enhanced Brain-Targeting Effect for General Anesthesia

Wu,

Shi,

Yang

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

Etomidate is a general anesthetic that has shown good hemodynamic stability without significant cardiovascular or respiratory depression. Despite several kinds of dosage forms having been reported for this drug, formulation types are very limited in clinical practice, and brain-targeted formulations for this central nervous system (CNS) drug have been rarely reported. Moreover, studies on the biocompatibility, toxicity, and anesthetic effects of the etomidate preparations in vivo were inadequate. The present study was to develop lactoferrin-modified liposomal etomidate (Eto-lip-LF) for enhanced drug distribution in the brain and improved anesthetic effects. Eto-lip-LF had good stability for storage and hemocompatibility for intravenous injection. Compared with the non-lactoferrin-containing liposomes, the lactoferrin-modified liposomes had notably enhanced brain-targeting ability in vivo, which was probably realized by the binding of transferrin with the transferrin and lactoferrin receptors highly distributed in the brain. Eto-lip-LF had a therapeutic index of about 25.3, higher than that of many other general anesthetics. Moreover, compared with the commercial etomidate emulsion, Eto-lip-LF could better achieve rapid onset of general anesthesia and rapid recovery from anesthesia, probably due to the enhanced drug delivery to the brain. The above results demonstrated the potential of this lactoferrin-modified liposomal etomidate to become an alternative preparation for clinical general anesthesia.

show abstract

Section: Introductionmentioning

confidence: 99%

In Vitro and In Vivo Evaluation of Lactoferrin-Modified Liposomal Etomidate with Enhanced Brain-Targeting Effect for General Anesthesia

Wu,

Shi,

Yang

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

show abstract

Demystifying the potential of lipid-based nanocarriers in targeting brain malignancies

Mesut,

Al-Mohaya,

Gholap

et al. 2024

Naunyn-Schmiedeberg's Arch Pharmacol

View full text Add to dashboard Cite

Biomimetic nanoparticle-driven strategies for targeted drug delivery in glioblastoma

Panchal,

Mutalik,

Manikkath

2024

J Nanopart Res

View full text Add to dashboard Cite

Glioblastoma (GBM), the most prevalent primary brain tumor in adults, remains highly challenging due to its invasive nature, limited treatment effectiveness, and short median survival durations. Standard of care includes surgery, radiation, chemotherapy, and tumor treating fields; however, there has been little improvement in survival rates. Biomimetic nanoparticles (NPs), coated with cell membranes and endogenous components, have immense potential for improving chemotherapy in GBM, by imitating cellular architecture and eluding immune clearance. With more individualized and efficient drug delivery, immunotherapeutic approaches and biomimetic NPs may increase patient survival rates. This article summarizes the main research on biomimetic NPs for GBM therapy, focusing on the classification, mechanisms, advantages, and challenges, along with the advancements in the development of GBM vaccines.

show abstract

Lipid-Based Nanocarriers in the Treatment of Glioblastoma Multiforme (GBM): Challenges and Opportunities

Cited by 5 publications

References 146 publications

In Vitro and In Vivo Evaluation of Lactoferrin-Modified Liposomal Etomidate with Enhanced Brain-Targeting Effect for General Anesthesia

In Vitro and In Vivo Evaluation of Lactoferrin-Modified Liposomal Etomidate with Enhanced Brain-Targeting Effect for General Anesthesia

Demystifying the potential of lipid-based nanocarriers in targeting brain malignancies

Biomimetic nanoparticle-driven strategies for targeted drug delivery in glioblastoma

Contact Info

Product

Resources

About